MET and cancer: In addition, we observed, that in HMVII cell line treated with foretinib as monotherapy, the pEGFR/EGFR ratio was increased, which may indicate that cancer cells compensate for the decreased pMET/MET ratio by increasing the pEGFR/EGFR ratio.